Receptor-type tyrosine-protein phosphatase C (CD45RA isoform) (CD45RA)

Receptor-type tyrosine-protein phosphatase C (PTPRC), specifically the CD45RA isoform, is a crucial transmembrane glycoprotein that regulates T-cell activation by modulating Src-family kinases such as Lck and Fyn (UniProt P08575). CD45RA is generated through alternative splicing of the PTPRC gene and is characteristically expressed on naive T cells, whereas memory T cells express the CD45RO isoform (PubMed: 24613458). In the context of therapeutic intervention, CD45RA is targeted primarily through selective cell depletion techniques in hematopoietic stem cell transplantation to prevent graft-versus-host disease (GvHD) (Blood: 124.21). By depleting CD45RA+ naive T cells from the donor graft, the risk of alloreactivity is significantly reduced while preserving the memory T cell repertoire necessary for post-transplant anti-viral and anti-fungal immunity (StatPearls: T-cell depletion). This selective approach is often preferred over pan-T-cell depletion, which can lead to severe infectious complications. Additionally, CD45RA serves as a key biomarker in clinical trials for assessing immune reconstitution and the impact of immunomodulatory drugs on specific T-cell subsets (NIH: ClinicalTrials.gov). Research is also exploring the use of CD45RA-targeted antibodies in treating certain types of leukemia and autoimmune disorders where naive T-cell populations drive pathology. Overall, CD45RA represents a pivotal target for fine-tuning the immune response in complex clinical scenarios.

Other names

PTPRCLeukocyte common antigenLCAT200CD45B220

Selective depletion of naive T cells (CD45RA+ cells) to reduce the risk of graft-versus-host disease while preserving memory T cell populations for pathogen protection.